National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran TANAFFOS (Respiration) 1735-0344 15 1 2016 01 01 Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV- Infected Patients 48 52 240241 EN Shadi Baniasadi Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, Shokoufeh Baradaran Shokouhi Virology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Payam Tabarsi Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Maryam Alehashem Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, Hossein Khalili Clinical Pharmacy Department, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran, Fanak Fahimi Chronic Respiratory Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Seyed Alireza Nadji Virology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Journal Article 2020 12 25 Background: Hypersensitivity reaction (HSR) is a major adverse effect of<br /> abacavir (ABC), which occurs in 5-8% of Caucasians. The relationship between<br /> Human Leukocyte Antigen (HLA) and ABC HSR has been reported in various<br /> populations. It has been proposed to administer ABC only to HLA-B*5701<br /> negative patients to avoid this reaction.<br /> The purpose of this study was to assess the prevalence of HLA-B*5701 in<br /> Iranian HIV positive patients. We also sought to find the relationship between<br /> this allele with ABC HSR in patients who received the medication.<br /> Materials and Methods: We screened patients for HLA-B*5701 allele using<br /> SybrGreen real time PCR-melting method on blood samples from HIV positive<br /> patients who were referred to our hospital. The quality of the extracted genome<br /> was evaluated by B-globin housekeeping gene as internal control prior to HLAB*5701 allele screening.<br /> Results: Of 198 HIV-infected patients, 6 (3.0%) had the HLA-B*5701 allele (95%<br /> CI, 1%–5%). Among the 28 patients who were given ABC, one individual had<br /> the HLA-B*5701 allele and experienced ABC HSR.<br /> Conclusion: Prevalence of HLA-B*5701 in Iranian patients was lower than that<br /> in Caucasians but was comparable with that of other Middle Eastern<br /> populations. Screening for HLA-B*5701 before ABC administration as part of<br /> antiretroviral therapy may reduce the risk of HSR.<br />   https://www.tanaffosjournal.ir/article_240241_9157b05674ec6f2aba55348c1a13d0da.pdf